ARS Pharmaceuticals, Inc. (SPRY) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Neffy in Schools Program Schools Joined | 10K | FY2026-Q1 |
| Healthcare Provider Adoption (Healthcare Providers Prescribed Neffy to Date) | 28K | FY2026-Q1 |
| Revenue from Supply Agreements | 2.74M | FY2026-Q1 |
| United States Net Product Revenue from Neffy Sales | 17.45M | FY2026-Q1 |
| Revenue Under Collaboration Agreements | 2.49M | FY2026-Q1 |
| Direct-to-Consumer Campaign Consumer Awareness | 56.00 percent | FY2025-Q3 |
| Overall Commercial Coverage | 93.00 percent | FY2025-Q2 |
| Allergists Enrolled in the Neffy Experience Program | 2.8K | FY2025-Q2 |
| Net Product Revenue | 7.76M | FY2025-Q1 |
| Healthcare Providers Directly Engaged | 10K | FY2025-Q1 |
Back to SPRY overview · SPRY earnings · SPRY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.